<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202773</url>
  </required_header>
  <id_info>
    <org_study_id>13732</org_study_id>
    <secondary_id>H9B-MC-BCDV</secondary_id>
    <nct_id>NCT01202773</nct_id>
  </id_info>
  <brief_title>A Study in Participants With Rheumatoid Arthritis</brief_title>
  <acronym>FLEX V</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to One or More TNF-α Inhibitors (FLEX V)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to help answer if LY2127399 is safe and effective in the
      treatment of rheumatoid arthritis in participants with an inadequate response to one or more
      tumor necrosis factor-alpha (TNF-α) inhibitors.

      This study is comprised of 2 periods:

      Period 1: 24-week blinded treatment

      Period 2: 48-week post-treatment follow-up
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated not based on safety concerns, but due to insufficient efficacy.
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>ACR Responder Index: composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: a ≥20% improvement from baseline in both 68 tender joint counts (TJC) and 66 swollen joint counts (SJC) and a ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). Percentage of participants achieving ACR20 response = (number of ACR20 responders / number of participants treated) * 100. All NR at Week 16, as well as all participants who discontinued study treatment at any time for any reason, were defined as NR starting at that time-point and going forward, including Week 24 endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>ACR Responder Index: composite of clinical, laboratory, and functional measures of RA. ACR50 Responder: had a ≥50% improvement from baseline in both 68 TJC and 66 SJC and a ≥50% improvement in at least 3 of 5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of Pt achieving ACR50 response = [number (No.) of ACR50 responders / No. of Pts treated]*100. ACR70 Responder: had a ≥70% improvement from baseline in both TJC and SJC and a ≥70% improvement in at least 3 of same 5 criteria for ACR50. Percentage of Pts achieving ACR70 response = (No. of ACR70 responders / No. of Pts treated)*100. All NR at Week 16, as well as all Pts who discontinued study treatment at any time for any reason, were defined as NR starting at that time-point and going forward, including Week 24 endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Percent Improvement (ACR-N)</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of either a) % change in TJC, b) % change in SJC, or c) the median % change of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to range of -100 to 100 to minimize impact of outliers (greater values indicate greater % improvement) and negative scores indicate a decline. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with treatment and region as fixed factors and baseline Disease Activity Score based on 28 joint counts -CRP (DAS28-CRP) as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Tender Joint Count (68 Joint Count)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Swollen Joint Count (66 Joint Count)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Participant's Assessment of Pain [Visual Analog Scale (VAS)]</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Participant's assessment of their current arthritis pain using VAS ranged from 0 millimeters (mm) (no pain) to 100 mm (worst possible pain). A decrease in pain score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Participant's Global Assessment of Disease Activity (VAS)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Participant's assessment of their current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Physician's Global Assessment of Disease Activity (VAS)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Physician's assessment of the participant's current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Disease Activity Score Based on 28 Joint Count and C-Reactive Protein Level (DAS28-CRP)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (milligrams per liter), and participant's global assessment of disease activity using VAS (participant global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. Scores ranged from 1.0 to 9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With DAS28-CRP Based European League Against Rheumatism (EULAR) Response</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>EULAR Responder index categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP=0.56*sqrt(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP &lt;3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or NR based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: &lt;3.2 or &gt;1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: &gt;5.1 or &lt;0.6 improvement from baseline). Percentage of participants with DAS28-CRP based EULAR response = ( number of participants with specific response) / (number of participants analyzed in the group) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Domain and Summary Scores</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, 2 component scores (CS), physical CS (PCS) and mental CS (MCS). Domain scores calculated by summing each item for each domain and transforming scores into 0-100 scale; higher scores indicated better health status. If &lt; 50% of the questions within a domain were answered, the raw score were not calculated. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher score indicating better mental or physical health. LS means were calculated using ANCOVA with treatment, region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Brief Fatigue Inventory (BFI) Individual Items and Impact Scores</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The BFI is a brief participant-reported questionnaire for the rapid assessment of fatigue severity and the impact of fatigue on daily functioning in the past 24 hours. The BFI contains 10 items; however, the first item is not included in the scoring of the scale as it asks about usual fatigue over the past week with the participant answering 'yes' or 'no'. The remaining 9 items assess fatigue severity (3 items) and impact of fatigue on daily functioning (6 items) using an 11-point numeric scale, with 0 = no fatigue and 10 = fatigue as bad as you can imagine. The fatigue impact subscale score is the average of the non-missing responses to 6 items: general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. If more than 3 items within the fatigue impact subscale were not answered by a participant, the subscale is set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Brief Pain Inventory Short Form (BPI-SF) Individual Items and Interference Scores</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The BPI-SF is a self-reported scale that measures the severity of pain based on the worst pain, least pain, average pain experienced during the past 24 hours and pain based on the pain right now, with scores ranging from 0 (no pain) to 10 (pain as severe as you can imagine). Pain interference score is the average of the responses in the past 24 hours to 7 items: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life [each item scored from 0 (does not interfere) to 10 (completely interferes)]. If more than 3 items of the Pain Interference Score are not answered by a participant, the score is set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Duration of Morning Stiffness (Minutes)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The Investigator asks participants about the duration of their morning stiffness (in minutes) in and around the joints and records the duration. The Investigator should ask participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration is longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ACR20 Response</measure>
    <time_frame>Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Absolute B Cell Counts</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Cell-surface marker cluster designation (CD) 3 negative, CD20 positive (CD3-CD20+) defines total mature B cells. B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. Baseline B cell count is the average of the values on or prior to the date of first injection of study treatment, including unscheduled visits. A positive or negative change indicated an increase or decrease, respectively in B cell count. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Serum Immunoglobulin (Ig) Levels</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Immunoglobulin (Ig), or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline in serum immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM) levels are reported. A negative change indicated a decrease in Ig levels. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics (PK): Constant Clearance</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>Population estimate of constant clearance as determined by population PK analysis. A 2-compartment model was used in PK modeling. Constant clearance is the PK parameter which describes the linear elimination of LY2127399 from serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-LY2127399 Antibodies</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>Participants with treatment-emergent anti-drug antibody (ADA) were participants who had any sample from baseline up to and through Week 52 that was a 4-fold increase (2-dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). Percentage of participants with ADA = (number of participants with treatment-emergent ADA) / (number of participants assessed) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in CRP</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>CRP is an indicator of inflammation. A negative change indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">456</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>120 milligrams (mg) LY2127399</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given every 4 weeks (Q4W) for 24 weeks. Participants receive a 240-mg loading dose when initiating treatment.
During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).
At Week 16, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period.
At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg LY2127399</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given Q2W for 24 weeks. Participants receive a 180-mg loading dose when initiating treatment.
At Week 16, both responders and NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Given Q2W for 24 weeks. Participants receive 2 injections of placebo when initiating treatment.
At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.
At Week 16, NR will receive a 180-mg loading dose of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2127399</intervention_name>
    <description>Administered Subcutaneously (SC)</description>
    <arm_group_label>120 milligrams (mg) LY2127399</arm_group_label>
    <arm_group_label>90 mg LY2127399</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Q4W</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>120 milligrams (mg) LY2127399</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Q2W</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA of more than 6 months and less than 15 years

          -  At least 8 tender and swollen joints

          -  An abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate
             (ESR)

          -  Positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP)
             antibody

          -  Previously treated with biologic TNF-α inhibitor therapy (infliximab, certolizumab,
             golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacy
             or intolerance

          -  Regular use of at least 1 conventional disease-modifying anti-rheumatic drug (DMARD),
             with a stable dose for at least 8 weeks prior to study start

          -  Woman must not be pregnant, breastfeeding, or become pregnant during the study

        Exclusion Criteria:

          -  Use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6
             weeks

          -  Steroid injection or intravenous (IV) infusion in the last 6 weeks

          -  Use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks

          -  History of a serious reaction to other biological DMARDs

          -  Use of an oral calcineurin inhibitor (for example, cyclosporin or tacrolimus) in the
             last 8 weeks

          -  Surgery on a joint or other major surgery less than 2 months ago, or plans to have
             joint surgery or major surgery during the study

          -  Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease,
             ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition
             except RA

          -  Cervical cancer or squamous skin cancer within the past 3 years, or other cancer
             within the past 5 years

          -  Received a live vaccine received within the past 12 weeks (for example, vaccines for
             measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)

          -  Hepatitis or human immunodeficiency virus (HIV)

          -  A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months
             or a serious bone or joint infection within 6 months

          -  Symptoms of herpes zoster or herpes simplex within the last month

          -  Active or latent tuberculosis (TB)

          -  Current symptoms of a serious disorder or illness

          -  Use of an investigational drug within the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <zip>92595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <zip>61201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cape Girardeau</city>
        <state>Missouri</state>
        <zip>63703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sanford</city>
        <state>North Carolina</state>
        <zip>27330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Limerick</city>
        <state>Pennsylvania</state>
        <zip>19468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <zip>29687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Córdoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lujan</city>
        <zip>6700</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mar Del Plata</city>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878DVC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Isidro</city>
        <zip>B1642AKG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>04266-010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malvern East</city>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Campinas</city>
        <zip>13059-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goiania</city>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Juiz De Fora</city>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>São Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orleans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint-Etienne Cedex 02</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Doberan</city>
        <zip>18209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baden-Baden</city>
        <zip>76530</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Munich</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haidari/Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Larissa</city>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arenzano</city>
        <zip>16011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gunma</city>
        <zip>370-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>673-1462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0122</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>162</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suwon-City</city>
        <zip>442-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Perak</city>
        <zip>30990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Putrajaya</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sarawak</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Col Centro</city>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>03720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tlalpan</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tauranga</city>
        <zip>3140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timaru</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plock</city>
        <zip>09-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Khanty-Mansiysk</city>
        <zip>628012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Benoni</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Limpopo</city>
        <zip>0380</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bilboa</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manises</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>March 24, 2018</results_first_submitted>
  <results_first_submitted_qc>May 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2018</results_first_posted>
  <disposition_first_submitted>April 14, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 14, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 7, 2014</disposition_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study had a treatment period (Weeks 0-24) and a post-treatment follow-up period (24-48 weeks in length). All participants were assessed for nonresponse at Week 16 with non-responders (NR) defined as participants with &lt;20% improvement from baseline in both tender and swollen joint counts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>120 mg LY2127399</title>
          <description>A loading dose of 240 milligrams (mg) (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered subcutaneously (SC) every 4 weeks (Q4W) for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo every 2 weeks (Q2W).
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
        </group>
        <group group_id="P2">
          <title>90 mg LY2127399</title>
          <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks.
At Week 16, both responders and NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 16 NR</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Post-Treatment Follow-Up Population</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96">Those who completed 24-week treatment period including both Week 16 responders and NR.</participants>
                <participants group_id="P2" count="105">Those who completed 24-week treatment period including both Week 16 responders and NR.</participants>
                <participants group_id="P3" count="100">Those who completed 24-week treatment period including both Week 16 responders and NR.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants, including participants who did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>120 mg LY2127399</title>
          <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
        </group>
        <group group_id="B2">
          <title>90 mg LY2127399</title>
          <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks.
At Week 16, both responders and NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="155"/>
            <count group_id="B4" value="456"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="11.6"/>
                    <measurement group_id="B2" value="51.3" spread="11.7"/>
                    <measurement group_id="B3" value="54.0" spread="11.1"/>
                    <measurement group_id="B4" value="53.2" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="381"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="339"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With American College of Rheumatology 20% (ACR20) Response</title>
        <description>ACR Responder Index: composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: a ≥20% improvement from baseline in both 68 tender joint counts (TJC) and 66 swollen joint counts (SJC) and a ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). Percentage of participants achieving ACR20 response = (number of ACR20 responders / number of participants treated) * 100. All NR at Week 16, as well as all participants who discontinued study treatment at any time for any reason, were defined as NR starting at that time-point and going forward, including Week 24 endpoint.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <population>All randomized participants with evaluable ACR20 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology 20% (ACR20) Response</title>
          <description>ACR Responder Index: composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: a ≥20% improvement from baseline in both 68 tender joint counts (TJC) and 66 swollen joint counts (SJC) and a ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). Percentage of participants achieving ACR20 response = (number of ACR20 responders / number of participants treated) * 100. All NR at Week 16, as well as all participants who discontinued study treatment at any time for any reason, were defined as NR starting at that time-point and going forward, including Week 24 endpoint.</description>
          <population>All randomized participants with evaluable ACR20 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="24.3"/>
                    <measurement group_id="O3" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response</title>
        <description>ACR Responder Index: composite of clinical, laboratory, and functional measures of RA. ACR50 Responder: had a ≥50% improvement from baseline in both 68 TJC and 66 SJC and a ≥50% improvement in at least 3 of 5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of Pt achieving ACR50 response = [number (No.) of ACR50 responders / No. of Pts treated]*100. ACR70 Responder: had a ≥70% improvement from baseline in both TJC and SJC and a ≥70% improvement in at least 3 of same 5 criteria for ACR50. Percentage of Pts achieving ACR70 response = (No. of ACR70 responders / No. of Pts treated)*100. All NR at Week 16, as well as all Pts who discontinued study treatment at any time for any reason, were defined as NR starting at that time-point and going forward, including Week 24 endpoint.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <population>All randomized participants with evaluable ACR50 or ACR70 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response</title>
          <description>ACR Responder Index: composite of clinical, laboratory, and functional measures of RA. ACR50 Responder: had a ≥50% improvement from baseline in both 68 TJC and 66 SJC and a ≥50% improvement in at least 3 of 5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of Pt achieving ACR50 response = [number (No.) of ACR50 responders / No. of Pts treated]*100. ACR70 Responder: had a ≥70% improvement from baseline in both TJC and SJC and a ≥70% improvement in at least 3 of same 5 criteria for ACR50. Percentage of Pts achieving ACR70 response = (No. of ACR70 responders / No. of Pts treated)*100. All NR at Week 16, as well as all Pts who discontinued study treatment at any time for any reason, were defined as NR starting at that time-point and going forward, including Week 24 endpoint.</description>
          <population>All randomized participants with evaluable ACR50 or ACR70 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology Percent Improvement (ACR-N)</title>
        <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of either a) % change in TJC, b) % change in SJC, or c) the median % change of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to range of -100 to 100 to minimize impact of outliers (greater values indicate greater % improvement) and negative scores indicate a decline. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with treatment and region as fixed factors and baseline Disease Activity Score based on 28 joint counts -CRP (DAS28-CRP) as a covariate.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <population>All randomized participants with evaluable ACR-N data. Modified Baseline Observation Carried Forward (mBOCF) was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology Percent Improvement (ACR-N)</title>
          <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of either a) % change in TJC, b) % change in SJC, or c) the median % change of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to range of -100 to 100 to minimize impact of outliers (greater values indicate greater % improvement) and negative scores indicate a decline. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with treatment and region as fixed factors and baseline Disease Activity Score based on 28 joint counts -CRP (DAS28-CRP) as a covariate.</description>
          <population>All randomized participants with evaluable ACR-N data. Modified Baseline Observation Carried Forward (mBOCF) was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of improvement</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.03" spread="4.00"/>
                    <measurement group_id="O2" value="-8.03" spread="4.11"/>
                    <measurement group_id="O3" value="-12.72" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Tender Joint Count (68 Joint Count)</title>
        <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable tender joint count data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Tender Joint Count (68 Joint Count)</title>
          <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable tender joint count data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>joint counts</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.37" spread="1.40"/>
                    <measurement group_id="O2" value="-6.08" spread="1.42"/>
                    <measurement group_id="O3" value="-6.56" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Swollen Joint Count (66 Joint Count)</title>
        <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable swollen joint count data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Swollen Joint Count (66 Joint Count)</title>
          <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable swollen joint count data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>joint counts</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.02" spread="0.98"/>
                    <measurement group_id="O2" value="-5.64" spread="1.00"/>
                    <measurement group_id="O3" value="-5.41" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Participant's Assessment of Pain [Visual Analog Scale (VAS)]</title>
        <description>Participant's assessment of their current arthritis pain using VAS ranged from 0 millimeters (mm) (no pain) to 100 mm (worst possible pain). A decrease in pain score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable participant's assessment of pain data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Participant's Assessment of Pain [Visual Analog Scale (VAS)]</title>
          <description>Participant's assessment of their current arthritis pain using VAS ranged from 0 millimeters (mm) (no pain) to 100 mm (worst possible pain). A decrease in pain score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable participant's assessment of pain data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.89" spread="2.10"/>
                    <measurement group_id="O2" value="-9.15" spread="2.15"/>
                    <measurement group_id="O3" value="-5.76" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Participant’s Global Assessment of Disease Activity (VAS)</title>
        <description>Participant's assessment of their current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable participant's global assessment of disease activity data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Participant’s Global Assessment of Disease Activity (VAS)</title>
          <description>Participant's assessment of their current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable participant's global assessment of disease activity data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.29" spread="2.14"/>
                    <measurement group_id="O2" value="-8.72" spread="2.19"/>
                    <measurement group_id="O3" value="-7.12" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Physician’s Global Assessment of Disease Activity (VAS)</title>
        <description>Physician's assessment of the participant's current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable physician's global assessment of disease activity data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Physician’s Global Assessment of Disease Activity (VAS)</title>
          <description>Physician's assessment of the participant's current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable physician's global assessment of disease activity data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.90" spread="2.16"/>
                    <measurement group_id="O2" value="-16.38" spread="2.23"/>
                    <measurement group_id="O3" value="-13.17" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
        <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable HAQ-DI data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable HAQ-DI data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.05"/>
                    <measurement group_id="O2" value="-0.09" spread="0.05"/>
                    <measurement group_id="O3" value="-0.08" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Disease Activity Score Based on 28 Joint Count and C-Reactive Protein Level (DAS28-CRP)</title>
        <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (milligrams per liter), and participant's global assessment of disease activity using VAS (participant global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. Scores ranged from 1.0 to 9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable DAS28-CRP data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Disease Activity Score Based on 28 Joint Count and C-Reactive Protein Level (DAS28-CRP)</title>
          <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (milligrams per liter), and participant's global assessment of disease activity using VAS (participant global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. Scores ranged from 1.0 to 9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable DAS28-CRP data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.12"/>
                    <measurement group_id="O2" value="-0.79" spread="0.13"/>
                    <measurement group_id="O3" value="-0.72" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With DAS28-CRP Based European League Against Rheumatism (EULAR) Response</title>
        <description>EULAR Responder index categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP=0.56*sqrt(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP &lt;3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or NR based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: &lt;3.2 or &gt;1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: &gt;5.1 or &lt;0.6 improvement from baseline). Percentage of participants with DAS28-CRP based EULAR response = ( number of participants with specific response) / (number of participants analyzed in the group) * 100.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <population>All randomized participants with evaluable EULAR response data. Modified Last Observation Carried Forward (mLOCF) was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DAS28-CRP Based European League Against Rheumatism (EULAR) Response</title>
          <description>EULAR Responder index categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP=0.56*sqrt(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP &lt;3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or NR based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: &lt;3.2 or &gt;1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: &gt;5.1 or &lt;0.6 improvement from baseline). Percentage of participants with DAS28-CRP based EULAR response = ( number of participants with specific response) / (number of participants analyzed in the group) * 100.</description>
          <population>All randomized participants with evaluable EULAR response data. Modified Last Observation Carried Forward (mLOCF) was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="9.6"/>
                    <measurement group_id="O3" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="36.3"/>
                    <measurement group_id="O3" value="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0"/>
                    <measurement group_id="O2" value="54.1"/>
                    <measurement group_id="O3" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Domain and Summary Scores</title>
        <description>SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, 2 component scores (CS), physical CS (PCS) and mental CS (MCS). Domain scores calculated by summing each item for each domain and transforming scores into 0-100 scale; higher scores indicated better health status. If &lt; 50% of the questions within a domain were answered, the raw score were not calculated. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher score indicating better mental or physical health. LS means were calculated using ANCOVA with treatment, region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable SF-36 domain and summary scores. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Domain and Summary Scores</title>
          <description>SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, 2 component scores (CS), physical CS (PCS) and mental CS (MCS). Domain scores calculated by summing each item for each domain and transforming scores into 0-100 scale; higher scores indicated better health status. If &lt; 50% of the questions within a domain were answered, the raw score were not calculated. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher score indicating better mental or physical health. LS means were calculated using ANCOVA with treatment, region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable SF-36 domain and summary scores. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.78"/>
                    <measurement group_id="O2" value="1.78" spread="0.82"/>
                    <measurement group_id="O3" value="1.00" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="0.75"/>
                    <measurement group_id="O2" value="2.95" spread="0.78"/>
                    <measurement group_id="O3" value="1.97" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitations due to Physical Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.72"/>
                    <measurement group_id="O2" value="2.08" spread="0.75"/>
                    <measurement group_id="O3" value="0.35" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitations due to Emotional Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.97"/>
                    <measurement group_id="O2" value="2.55" spread="1.01"/>
                    <measurement group_id="O3" value="1.19" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health Perception</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.64"/>
                    <measurement group_id="O2" value="0.91" spread="0.67"/>
                    <measurement group_id="O3" value="1.88" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.85"/>
                    <measurement group_id="O2" value="1.57" spread="0.88"/>
                    <measurement group_id="O3" value="0.98" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" spread="0.87"/>
                    <measurement group_id="O2" value="1.68" spread="0.91"/>
                    <measurement group_id="O3" value="1.32" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="0.77"/>
                    <measurement group_id="O2" value="2.40" spread="0.80"/>
                    <measurement group_id="O3" value="2.05" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="0.71"/>
                    <measurement group_id="O2" value="1.83" spread="0.74"/>
                    <measurement group_id="O3" value="1.21" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.87"/>
                    <measurement group_id="O2" value="1.86" spread="0.90"/>
                    <measurement group_id="O3" value="1.38" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Brief Fatigue Inventory (BFI) Individual Items and Impact Scores</title>
        <description>The BFI is a brief participant-reported questionnaire for the rapid assessment of fatigue severity and the impact of fatigue on daily functioning in the past 24 hours. The BFI contains 10 items; however, the first item is not included in the scoring of the scale as it asks about usual fatigue over the past week with the participant answering 'yes' or 'no'. The remaining 9 items assess fatigue severity (3 items) and impact of fatigue on daily functioning (6 items) using an 11-point numeric scale, with 0 = no fatigue and 10 = fatigue as bad as you can imagine. The fatigue impact subscale score is the average of the non-missing responses to 6 items: general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. If more than 3 items within the fatigue impact subscale were not answered by a participant, the subscale is set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable BFI data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Brief Fatigue Inventory (BFI) Individual Items and Impact Scores</title>
          <description>The BFI is a brief participant-reported questionnaire for the rapid assessment of fatigue severity and the impact of fatigue on daily functioning in the past 24 hours. The BFI contains 10 items; however, the first item is not included in the scoring of the scale as it asks about usual fatigue over the past week with the participant answering 'yes' or 'no'. The remaining 9 items assess fatigue severity (3 items) and impact of fatigue on daily functioning (6 items) using an 11-point numeric scale, with 0 = no fatigue and 10 = fatigue as bad as you can imagine. The fatigue impact subscale score is the average of the non-missing responses to 6 items: general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. If more than 3 items within the fatigue impact subscale were not answered by a participant, the subscale is set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable BFI data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue - Now</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.12"/>
                    <measurement group_id="O2" value="-0.55" spread="0.12"/>
                    <measurement group_id="O3" value="-0.60" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue – Usual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.11"/>
                    <measurement group_id="O2" value="-0.58" spread="0.11"/>
                    <measurement group_id="O3" value="-0.56" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue – Worst</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.12"/>
                    <measurement group_id="O2" value="-0.65" spread="0.12"/>
                    <measurement group_id="O3" value="-0.72" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.12"/>
                    <measurement group_id="O2" value="-0.50" spread="0.12"/>
                    <measurement group_id="O3" value="-0.52" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.12"/>
                    <measurement group_id="O2" value="-0.35" spread="0.12"/>
                    <measurement group_id="O3" value="-0.35" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking Ability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.12"/>
                    <measurement group_id="O2" value="-0.38" spread="0.13"/>
                    <measurement group_id="O3" value="-0.36" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.12"/>
                    <measurement group_id="O2" value="-0.46" spread="0.12"/>
                    <measurement group_id="O3" value="-0.42" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relations with Other People</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.12"/>
                    <measurement group_id="O2" value="-0.43" spread="0.12"/>
                    <measurement group_id="O3" value="-0.29" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.13"/>
                    <measurement group_id="O2" value="-0.55" spread="0.13"/>
                    <measurement group_id="O3" value="-0.41" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Impact Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.11"/>
                    <measurement group_id="O2" value="-0.43" spread="0.11"/>
                    <measurement group_id="O3" value="-0.39" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Brief Pain Inventory Short Form (BPI-SF) Individual Items and Interference Scores</title>
        <description>The BPI-SF is a self-reported scale that measures the severity of pain based on the worst pain, least pain, average pain experienced during the past 24 hours and pain based on the pain right now, with scores ranging from 0 (no pain) to 10 (pain as severe as you can imagine). Pain interference score is the average of the responses in the past 24 hours to 7 items: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life [each item scored from 0 (does not interfere) to 10 (completely interferes)]. If more than 3 items of the Pain Interference Score are not answered by a participant, the score is set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable BPI-SF scores. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Brief Pain Inventory Short Form (BPI-SF) Individual Items and Interference Scores</title>
          <description>The BPI-SF is a self-reported scale that measures the severity of pain based on the worst pain, least pain, average pain experienced during the past 24 hours and pain based on the pain right now, with scores ranging from 0 (no pain) to 10 (pain as severe as you can imagine). Pain interference score is the average of the responses in the past 24 hours to 7 items: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life [each item scored from 0 (does not interfere) to 10 (completely interferes)]. If more than 3 items of the Pain Interference Score are not answered by a participant, the score is set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable BPI-SF scores. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain - Worst</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.2"/>
                    <measurement group_id="O2" value="-0.8" spread="0.2"/>
                    <measurement group_id="O3" value="-0.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Least</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.2"/>
                    <measurement group_id="O2" value="-0.5" spread="0.2"/>
                    <measurement group_id="O3" value="-0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Average</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.2"/>
                    <measurement group_id="O2" value="-0.7" spread="0.2"/>
                    <measurement group_id="O3" value="-0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Now</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.2"/>
                    <measurement group_id="O2" value="-0.5" spread="0.2"/>
                    <measurement group_id="O3" value="-0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.2"/>
                    <measurement group_id="O2" value="-0.4" spread="0.2"/>
                    <measurement group_id="O3" value="-0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.2"/>
                    <measurement group_id="O2" value="-0.2" spread="0.2"/>
                    <measurement group_id="O3" value="-0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking Ability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.2"/>
                    <measurement group_id="O2" value="-0.4" spread="0.2"/>
                    <measurement group_id="O3" value="-0.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Work</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.2"/>
                    <measurement group_id="O2" value="-0.4" spread="0.2"/>
                    <measurement group_id="O3" value="-0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relations with Other People</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.2"/>
                    <measurement group_id="O2" value="-0.2" spread="0.2"/>
                    <measurement group_id="O3" value="-0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.2"/>
                    <measurement group_id="O2" value="-0.3" spread="0.2"/>
                    <measurement group_id="O3" value="-0.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of Life</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.2"/>
                    <measurement group_id="O2" value="-0.4" spread="0.2"/>
                    <measurement group_id="O3" value="-0.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.2"/>
                    <measurement group_id="O2" value="-0.3" spread="0.2"/>
                    <measurement group_id="O3" value="-0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Duration of Morning Stiffness (Minutes)</title>
        <description>The Investigator asks participants about the duration of their morning stiffness (in minutes) in and around the joints and records the duration. The Investigator should ask participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration is longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable morning stiffness data; mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Duration of Morning Stiffness (Minutes)</title>
          <description>The Investigator asks participants about the duration of their morning stiffness (in minutes) in and around the joints and records the duration. The Investigator should ask participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration is longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable morning stiffness data; mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" spread="11.5"/>
                    <measurement group_id="O2" value="-1.0" spread="11.7"/>
                    <measurement group_id="O3" value="-18.0" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to ACR20 Response</title>
        <time_frame>Baseline through Week 24</time_frame>
        <population>Zero participants analyzed. Time to ACR20 data not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to ACR20 Response</title>
          <population>Zero participants analyzed. Time to ACR20 data not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Absolute B Cell Counts</title>
        <description>Cell-surface marker cluster designation (CD) 3 negative, CD20 positive (CD3-CD20+) defines total mature B cells. B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. Baseline B cell count is the average of the values on or prior to the date of first injection of study treatment, including unscheduled visits. A positive or negative change indicated an increase or decrease, respectively in B cell count. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable CD3-CD20+ B cell counts. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Absolute B Cell Counts</title>
          <description>Cell-surface marker cluster designation (CD) 3 negative, CD20 positive (CD3-CD20+) defines total mature B cells. B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. Baseline B cell count is the average of the values on or prior to the date of first injection of study treatment, including unscheduled visits. A positive or negative change indicated an increase or decrease, respectively in B cell count. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable CD3-CD20+ B cell counts. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>cells/microliter (cells/µL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.3" spread="9.9"/>
                    <measurement group_id="O2" value="-65.8" spread="10.1"/>
                    <measurement group_id="O3" value="3.2" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Serum Immunoglobulin (Ig) Levels</title>
        <description>Immunoglobulin (Ig), or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline in serum immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM) levels are reported. A negative change indicated a decrease in Ig levels. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable serum Ig data. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Serum Immunoglobulin (Ig) Levels</title>
          <description>Immunoglobulin (Ig), or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline in serum immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM) levels are reported. A negative change indicated a decrease in Ig levels. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable serum Ig data. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>grams/liter (g/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.330" spread="0.049"/>
                    <measurement group_id="O2" value="-0.324" spread="0.050"/>
                    <measurement group_id="O3" value="0.003" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.955" spread="0.161"/>
                    <measurement group_id="O2" value="-0.978" spread="0.163"/>
                    <measurement group_id="O3" value="0.058" spread="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.273" spread="0.043"/>
                    <measurement group_id="O2" value="-0.239" spread="0.044"/>
                    <measurement group_id="O3" value="-0.019" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetics (PK): Constant Clearance</title>
        <description>Population estimate of constant clearance as determined by population PK analysis. A 2-compartment model was used in PK modeling. Constant clearance is the PK parameter which describes the linear elimination of LY2127399 from serum.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <population>All randomized participants who received at least 1 dose of LY2127399 with evaluable LY2127399 PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks or a loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period or 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Population Pharmacokinetics (PK): Constant Clearance</title>
          <description>Population estimate of constant clearance as determined by population PK analysis. A 2-compartment model was used in PK modeling. Constant clearance is the PK parameter which describes the linear elimination of LY2127399 from serum.</description>
          <population>All randomized participants who received at least 1 dose of LY2127399 with evaluable LY2127399 PK data.</population>
          <units>milliliters/hour (mL/h)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="3.58" lower_limit="3.44" upper_limit="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Developing Anti-LY2127399 Antibodies</title>
        <description>Participants with treatment-emergent anti-drug antibody (ADA) were participants who had any sample from baseline up to and through Week 52 that was a 4-fold increase (2-dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). Percentage of participants with ADA = (number of participants with treatment-emergent ADA) / (number of participants assessed) * 100.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug with an evaluable baseline ADA result and a post-baseline ADA result. Participants missing an evaluable baseline result with all negative post-baseline results were included. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Developing Anti-LY2127399 Antibodies</title>
          <description>Participants with treatment-emergent anti-drug antibody (ADA) were participants who had any sample from baseline up to and through Week 52 that was a 4-fold increase (2-dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). Percentage of participants with ADA = (number of participants with treatment-emergent ADA) / (number of participants assessed) * 100.</description>
          <population>All randomized participants who received at least 1 dose of study drug with an evaluable baseline ADA result and a post-baseline ADA result. Participants missing an evaluable baseline result with all negative post-baseline results were included. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in CRP</title>
        <description>CRP is an indicator of inflammation. A negative change indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with evaluable CRP data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in CRP</title>
          <description>CRP is an indicator of inflammation. A negative change indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable CRP data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>milligrams/liter (mg/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="1.83"/>
                    <measurement group_id="O2" value="0.95" spread="1.87"/>
                    <measurement group_id="O3" value="2.93" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY 120 mg Q4W, Randomized Treatment Period</title>
          <description>A loading dose of 240 mg of LY2127399 (2 injections of 120 mg) followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
The Randomized Treatment Period was defined as the time all data was collected during the treatment period, excluding the data collected after the date of the Week 16 injection for the Week 16 NR.</description>
        </group>
        <group group_id="E2">
          <title>LY 90 mg Q2W, Randomized Treatment Period</title>
          <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
The Randomized Treatment Period was defined as the time all data was collected during the treatment period, excluding the data collected after the date of the Week 16 injection for the Week 16 NR.</description>
        </group>
        <group group_id="E3">
          <title>Placebo, Randomized Treatment Period</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.
The Randomized Treatment Period was defined as the time all data was collected during the treatment period, excluding the data collected after the date of the Week 16 injection for the Week 16 NR.</description>
        </group>
        <group group_id="E4">
          <title>LY 120 mg Q4W, Rescue Period</title>
          <description>A loading dose of 240 mg of LY2127399 (2 injections of 120 mg) followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 16 weeks. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
The Rescue Treatment Period was defined as all data collected after the date of the Week 16 injection during the treatment period for Week 16 NR.</description>
        </group>
        <group group_id="E5">
          <title>LY 90 mg Q2W, Rescue Period</title>
          <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 16 weeks.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
The Rescue Treatment Period was defined as all data collected after the date of the Week 16 injection during the treatment period for Week 16 NR.</description>
        </group>
        <group group_id="E6">
          <title>Placebo, Rescue Period</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 16 weeks.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
The Rescue Treatment Period was defined as all data collected after the date of the Week 16 injection during the treatment period for Week 16 NR.</description>
        </group>
        <group group_id="E7">
          <title>LY 120 mg Q4W, Follow-up Period</title>
          <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 24 weeks. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E8">
          <title>LY 90 mg Q2W, Follow-up Period</title>
          <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 24 weeks. At Week 16, both responders and NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E9">
          <title>Placebo, Follow-up Period</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 24 weeks. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E10">
          <title>LY 120 mg Q4W to LY 90 mg Q2W (Week 16), Follow-up Period</title>
          <description>A loading dose of 240 mg of LY2127399 (2 injections of 120 mg) followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 16 weeks. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E11">
          <title>Placebo to LY 90 mg Q2W (Week 16), Follow-up Period</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of 1 injection of placebo administered SC Q2W for 16 weeks.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
The Post-Treatment Follow-Up Period started after Week 24 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="18" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E3" events="21" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" events="19" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="10" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Alveolar osteitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vitamin d deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Dysplastic naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study has been terminated not based on safety concerns, but due to insufficient efficacy. Early termination led to lower than expected enrollment and was responsible for the large number of discontinuation reason as Sponsor Decision.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

